Prelude Therapeutics INC (PRLD) — 8-K Filings

All 8-K filings from Prelude Therapeutics INC. Browse 16 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (16)

Prelude Therapeutics Files 8-K with Exhibits — Apr 20, 2026 Risk: low
On April 20, 2026, Prelude Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibit
8-K Filing — Apr 15, 2026
8-K Filing — Nov 4, 2025
Prelude Therapeutics Announces CMO Departure, Appoints Interim — Oct 17, 2025 Risk: medium
On October 15, 2025, Prelude Therapeutics Incorporated announced the departure of Dr. Christopher V. Fountas as Chief Medical Officer. The company also announce
Prelude Therapeutics Files 8-K — Sep 19, 2025 Risk: low
On September 18, 2025, Prelude Therapeutics Incorporated announced an "Other Event" in a Form 8-K filing. The specific nature of this event is not detailed in t
Prelude Therapeutics Appoints New Director — Jun 13, 2025 Risk: low
On June 11, 2025, Prelude Therapeutics Incorporated announced the election of Dr. Jonathan G. Drachman to its Board of Directors. Dr. Drachman, who has extensiv
Prelude Therapeutics Files 8-K Report — Apr 25, 2025 Risk: low
On April 25, 2025, Prelude Therapeutics Incorporated filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorpo
Prelude Therapeutics Faces Nasdaq Delisting Notice — Mar 28, 2025 Risk: high
Prelude Therapeutics Incorporated announced on March 27, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued lis
Prelude Therapeutics Files 8-K: Officer/Director Changes & Financials — Feb 5, 2025 Risk: medium
On February 3, 2025, Prelude Therapeutics Incorporated filed an 8-K report detailing the departure of certain officers and directors, the election of new direct
Prelude Therapeutics Files 8-K — Dec 11, 2024 Risk: low
On December 11, 2024, Prelude Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpora
8-K Filing — Oct 24, 2024
Prelude Therapeutics Files 8-K Report — Sep 13, 2024 Risk: low
On September 13, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibit
Prelude Therapeutics Files 8-K Report — Sep 9, 2024 Risk: low
On September 9, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
Prelude Therapeutics Files 8-K on Shareholder Vote Matters — Jun 18, 2024 Risk: low
On June 14, 2024, Prelude Therapeutics Incorporated filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indica
Prelude Therapeutics Files 8-K — Jun 12, 2024 Risk: low
On June 12, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exh
Prelude Therapeutics Appoints New Chief Medical Officer — Apr 10, 2024 Risk: medium
On April 8, 2024, Prelude Therapeutics Incorporated announced the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer. Dr. Drachman previously serv

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX